Leserbrief
Does the Composite Endpoint Overstate Risk After Denosumab Discontinuation?
Clinical Oncology · 2026-07 · 55 · 104170
DOI: 10.1016/j.clon.2026.104170 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Oncology, 2026-07. Verfasst von Y Xue und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, China. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Radiotherapy, Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, China.
- Department of Radiotherapy, Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, China. Electronic address: 13834534594@163.com.
Zitieren
APA
Xue, Y., & Yan, J. (2026). Does the Composite Endpoint Overstate Risk After Denosumab Discontinuation?. Clinical Oncology, 55, 104170. https://doi.org/10.1016/j.clon.2026.104170
Vancouver
Xue Y, Yan J. Does the Composite Endpoint Overstate Risk After Denosumab Discontinuation?. Clinical Oncology. 2026;55:104170. doi:10.1016/j.clon.2026.104170
BibTeX
@article{Xue2026,
author = {Xue, Y and Yan, J},
title = {Does the Composite Endpoint Overstate Risk After Denosumab Discontinuation?},
journal = {Clinical Oncology},
year = {2026},
volume = {55},
pages = {104170},
doi = {10.1016/j.clon.2026.104170}
}
EUVIMED